Diaceutics (LSE:DXRX) ROCE %: 16.78% (As of Dec. 2025)


LSE:DXRX Diaceutics PLC LSE:DXRX
92 GF Score
Price £1.45
GF Value £1.91
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Diaceutics ROCE %?

Diaceutics LSE:DXRX 92 ROCE % is 16.78% as of Dec. 2025. GuruFocus rates LSE:DXRX with a GF Score™ of 92/100 and a GF Value™ of £1.91 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Diaceutics's annualized ROCE % for the quarter that ended in Dec. 2025 was 16.78%.

Diaceutics  (LSE:DXRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Diaceutics ROCE % Related Terms

Diaceutics ROCE % Historical Data

* Premium members only.

The historical data trend for Diaceutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics ROCE % Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 1.57 -5.49 -4.48 0.87

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.17 -15.83 6.85 -15.09 16.78
LSE:DXRX
92GF Score
Diaceutics PLC LSE:DXRX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diaceutics ROCE % Calculation

Diaceutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=0.36/( ( (48.62 - 7.765) + (50.008 - 8.551) )/ 2 )
=0.36/( (40.855+41.457)/ 2 )
=0.36/41.156
=0.87 %

Diaceutics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=6.688/( ( (44.423 - 6.184) + (50.008 - 8.551) )/ 2 )
=6.688/( ( 38.239 + 41.457 )/ 2 )
=6.688/39.848
=16.78 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.78% mean?
Diaceutics (LSE:DXRX) has a ROCE % of 16.78% as of Dec. 2025.
Is Diaceutics' ROCE % too high?
Diaceutics' current ROCE % is 16.78%. The Healthcare Providers & Services industry median ROCE % is 6.41. Diaceutics' value of 16.78% is 161.8% above this industry median. Overall, Diaceutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' ROCE % compare to VEEV and BTSG?
Diaceutics' ROCE % of 16.78% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Diaceutics' value of 16.78% is 161.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current ROCE % of 16.78% is 161.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current ROCE % is 16.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (LSE:DXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is £1.91, compared to a current price of £1.45 — trading 24.1% below its estimated fair value. The current ROCE % is 16.78% and 161.8% above the Healthcare Providers & Services industry median of 6.41. Diaceutics' overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Diaceutics (LSE:DXRX), the current ROCE % is 16.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diaceutics (LSE:DXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of £1.45 is trading 24.1% below its estimated GF Value™ of £1.91. GuruFocus considers Diaceutics to be Modestly Undervalued.

Key valuation signals for LSE:DXRX:

  • ROCE %: 16.78%
  • GF Value™: £1.91 vs. price of £1.45 (24.1% below fair value)
  • GF Score™: 92/100 with 1 warning sign
  • Industry Position: 161.8% above the Healthcare Providers & Services median

No single metric tells the full story. See the LSE:DXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diaceutics Business Description

Other Exchanges DIUXF:USA7DC:Germany
Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
92GF Score

Get the complete analysis for LSE:DXRX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.45
Price
£1.91
GF Value